Comparison of Ciprofol-Based and Propofol-Based Total Intravenous Anesthesia on Microvascular Decompression of Facial Nerve with Neurophysiological Monitoring: A Randomized Non-Inferiority Trial
Open Access
- 1 June 2024
- journal article
- research article
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 18, 2475-2484
Abstract
Purpose: Ciprofol is a recently developed short-acting gamma-aminobutyric acid receptor agonist with a higher potency than that of propofol. As a new sedative drug, there are few clinical studies on ciprofol. We sought to examine the safety and efficacy of ciprofol use for general anesthesia in neurosurgical individuals undergoing neurosurgical surgery with intraoperative neurophysiological monitoring (IONM). Patients and Methods: This single-center, non-inferiority, single-blind, randomized controlled trial was conducted from September 13, 2022 to September 22, 2023. 120 patients undergoing elective microvascular decompression surgery (MVD) with IONM were randomly assigned to receive either ciprofol or propofol. The primary outcome of this study was the amplitude of intraoperative compound muscle action potential decline, and the secondary outcome included the indexes related to neurophysiological monitoring and anesthesia outcomes. Results: The mean values of the primary outcome in the ciprofol group and the propofol group were 64.7± 44.1 and 53.4± 35.4, respectively. Furthermore, the 95% confidence interval of the difference was − 25.78 to 3.12, with the upper limit of the difference being lower than the non-inferiority boundary of 6.6. Ciprofol could achieve non-inferior effectiveness in comparison with propofol in IONM of MVD. The result during anesthesia induction showed that the magnitude of the blood pressure drop and the incidence of injection pain in the ciprofol group were significantly lower than those in the propofol group (P< 0.05). The sedative drug and norepinephrine consumption in the ciprofol group was significantly lower than that in the propofol group (P< 0.05). Conclusion: Ciprofol is not inferior to propofol in the effectiveness and safety of IONM and the surgical outcome. Concurrently, ciprofol is more conducive to reducing injection pain and improving hemodynamic stability, which may be more suitable for IONM-related surgery, and has a broad application prospect.Keywords
This publication has 27 references indexed in Scilit:
- Sedation Effects Produced by a Ciprofol Initial Infusion or Bolus Dose Followed by Continuous Maintenance Infusion in Healthy Subjects: A Phase 1 TrialAdvances in Therapy, 2021
- Efficacy and safety of ciprofol for the sedation/anesthesia in patients undergoing colonoscopy: Phase IIa and IIb multi-center clinical trialsEuropean Journal of Pharmaceutical Sciences, 2021
- Efficacy and Safety of Ciprofol Sedation in ICU Patients with Mechanical Ventilation: A Clinical Trial Study ProtocolAdvances in Therapy, 2021
- Propofol detection for monitoring of intravenous anaesthesia: a reviewJournal of Clinical Monitoring and Computing, 2021
- Predicting outcome of hemifacial spasm after microvascular decompression with intraoperative monitoring: A systematic reviewHeliyon, 2021
- Mechanisms contributing to hypotension after anesthetic induction with sufentanil, propofol, and rocuronium: a prospective observational studyJournal of Clinical Monitoring and Computing, 2021
- Intraoperative hypotension and the risk of postoperative adverse outcomes: a systematic reviewBritish Journal of Anaesthesia, 2018
- Vasopressors induce passive pulmonary hypertension by blood redistribution from systemic to pulmonary circulationBasic Research in Cardiology, 2017
- Comparision of clonidine and dexmedetomidine for attenuation of laryngoscopy and intubation response – A randomized controlled trialJournal of Clinical Anesthesia, 2016
- Propofol infusion for induction and maintenance of anesthesia in elderly patients: Recovery and hemodynamic profilesJournal of Clinical Anesthesia, 1996